XORTX Therapeutics Inc. (XRTX) Dividend History

Company News

• XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

  XORTX Therapeutics Inc. received notification from Nasdaq that it is not in compliance with the minimum bid price requirement, but the company plans to evaluate options to regain compliance. The company also provided updates on its drug development programs.

  GlobeNewswire Inc.
• XORTX Announces Change of Auditor

  XORTX Therapeutics Inc. has changed its auditor from Smythe LLP to Davidson & Company LLP, effective January 16, 2025. The change was approved by the company's board of directors and there were no reservations in the former auditor's reports.

  GlobeNewswire Inc.
• XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

  XORTX Therapeutics Inc. reminds shareholders of the upcoming deadline to vote at the company's Annual General and Special Meeting on September 12, 2024. The Board of Directors recommends that shareholders vote for all proposed items, including fixing the number of directors, electing the board, appointing the auditor, and approving the company's amended Stock Option Plan.

  GlobeNewswire Inc.
• XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

  CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press releases of March 11 and April 30, 2024, the Company has received TSX Venture Exchange (“TSXV”) approval to amend the terms of the balance of outstanding common share purchase warrants (“Warrants”) that were issued on October 15, 2021. Reference is made to the Company’s press release of October 7, 2022 wherein the Company indicated that the Warrants had been repriced in connection with the October 7, 2022 private placement, however that process was not completed at the time. The re-pricing approval received affects an original 910,000 warrants (101,111 post 9:1 consolidation). The Warrants had an original exercise price of USD $42.93 (CAD $53.10) (adjusted up from USD $4.77 to USD $42.93 per share as a result of the 9:1 consolidation). The TSXV has now approved an amended exercise price of USD $5.00 (on a post-consolidation basis) and the acceleration provision outlined below.

  GlobeNewswire Inc.
• XORTX Reprices Warrants Issued in Connection with Previous Private Placements

  CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press release of March 11, 2024, the Company has received TSX Venture Exchange approval to amend the terms of an aggregate of 1,024,099 outstanding common share purchase warrants (“Warrants”) by amending the exercise price to USD $5.00 per share as follows:

  GlobeNewswire Inc.